OmniAb SPAC Presentation Deck

OMNIAB CLINICAL AND APPROVED PARTNER PIPELINE TWO APPROVED PRODUCTS AND 23 CLINICAL OMNIAB-DERIVED ANTIBODIES Partner gloria 誉衡生物 ARCUS 基石药业 BIOSCIENCES CSTONE PHARMACEUTICAS Janssen Johan Jokureu Genentech* A Member of the Bocke Group HANALL HARBOUR IMMUNOVANT Genmab Aptevo Janssen John Acken Janssen Janssen Johna Jakuen Merck Genmab symphogen symphogen symphogen! symphagen abbviet Ancora AMGEN + SalubrisBio O CURON Zhilkang Hongyi Boehringer Ingelheim Program Zimberelimab OmniRat Sugemalimab OmniRat OmniRat Teclistamab OmniRat OmniRat OmniRat OmniMouse OmniMouse OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniFlic OmniFlic OmniFlic OmniRat OmniRat OmniRat OmniChicken Tiragolumab Batoclimab GEN1046 APVO436 JNJ-67371244 JNJ-70218902 JNJ-78306358 M6223 GEN1047 SYM022 SYM023 SYM024 S095029 TNB-383B TNB-486 AMG 340 SAL003 CN1 Source Animal Undisclosed Undisclosed Area Oncology Oncology Oncology Oncology Immunology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Metabolic Oncology Oncology Undisclosed Target PD-1 PD-L1 BCMA x CD3 TIGIT FcRn PD-L1 x 4-1BB CD123 x CD3 CD33 x CD3 Undisclosed HLA-G x CD3 TIGIT B7H4 x CD3 LAG-3 TIM-3 CD73 NKG2A BCMA x CD3 CD19 x CD3 PSMA x CD3 PCSK9 Undisclosed 4-1BB Undisclosed Preclinical Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020 Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved in China. Phase 1 * Indicates programs with fully paid licenses. + Programs discovered by Teneobio under a fully paid licenses. Future programs discovered under license agreement are subject to downstream economics. Phase 2 Phase 3 Registration Approved 24 OmniAb

View entire presentation